Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$195.14 +1.5%	$196.75	$153.58 ▼ $218.66	$345.19B	0.55	7.21 million shs	3.26 million shs
BMY Bristol-Myers Squibb	$49.39 +1.9%	$56.24	$39.35 ▼ $63.33	$100.49B	0.41	12.66 million shs	9.39 million shs
JNJ Johnson & Johnson	$156.44 +0.7%	$159.43	$140.68 ▼ $169.99	$376.40B	0.49	9.67 million shs	2.45 million shs
MRK Merck & Co., Inc.	$84.85 +2.0%	$87.00	$75.93 ▼ $134.63	$213.97B	0.4	16.36 million shs	7.69 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+3.48%	+13.19%	-6.19%	+10.03%	+20.56%
BMY Bristol-Myers Squibb	+1.23%	-1.02%	-19.38%	-17.67%	+8.03%
JNJ Johnson & Johnson	+0.53%	-1.04%	-5.05%	+3.14%	+6.31%
MRK Merck & Co., Inc.	+0.45%	+6.79%	-6.71%	-14.66%	-36.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.5961 of 5 stars	2.4	4.0	4.2	3.9	2.7	2.5	1.3
BMY Bristol-Myers Squibb	4.5039 of 5 stars	3.2	3.0	4.2	4.0	2.1	3.3	0.0
JNJ Johnson & Johnson	4.6824 of 5 stars	3.3	3.0	4.2	3.9	3.3	2.5	0.6
MRK Merck & Co., Inc.	5 of 5 stars	4.3	3.0	5.0	3.9	3.9	3.3	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.89	Moderate Buy	$211.41	8.34% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$58.00	17.44% Upside
JNJ Johnson & Johnson	2.63	Moderate Buy	$171.82	9.84% Upside
MRK Merck & Co., Inc.	2.59	Moderate Buy	$111.13	30.97% Upside

Current Analyst Ratings Breakdown

Latest BMY, JNJ, ABBV, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/25/2025	BMY Bristol-Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol-Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/24/2025	JNJ Johnson & Johnson	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/23/2025	BMY Bristol-Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$210.00
4/22/2025	BMY Bristol-Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol-Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
4/22/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$85.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.13	$14.42 per share	13.53	$1.90 per share	102.70
BMY Bristol-Myers Squibb	$47.64B	2.11	$5.21 per share	9.48	$8.08 per share	6.11
JNJ Johnson & Johnson	$89.33B	4.21	$12.85 per share	12.17	$29.69 per share	5.27
MRK Merck & Co., Inc.	$63.92B	3.35	$2.94 per share	28.82	$14.85 per share	5.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	81.31	13.96	1.62	7.59%	296.28%	12.65%	N/A
BMY Bristol-Myers Squibb	-$8.95B	$2.67	N/A	8.11	2.07	-18.53%	13.93%	2.46%	N/A
JNJ Johnson & Johnson	$14.07B	$8.99	23.52	14.13	2.56	18.20%	34.24%	13.63%	7/16/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	12.61	8.57	0.77	26.67%	45.35%	17.36%	N/A

Latest BMY, JNJ, ABBV, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	BMY Bristol-Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion
1/31/2025	Q4 2024	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.36%	+6.04%	279.15%	53 Years
BMY Bristol-Myers Squibb	$2.48	5.02%	+6.38%	92.88%	17 Years
JNJ Johnson & Johnson	$5.20	3.32%	+5.43%	57.84%	64 Years
MRK Merck & Co., Inc.	$3.24	3.82%	+5.73%	47.16%	14 Years

Latest BMY, JNJ, ABBV, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
BMY Bristol-Myers Squibb	2.90	1.25	1.15
JNJ Johnson & Johnson	0.43	1.11	0.86
MRK Merck & Co., Inc.	0.79	1.36	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol-Myers Squibb	76.41%
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol-Myers Squibb	0.09%
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	69,000	2.52 billion	2.53 billion	Optionable

BMY, JNJ, ABBV, and MRK Headlines

Recent News About These Companies

Merck & Co., Inc. (NYSE:MRK) Trading Up 0.9% - What's Next?

April 29 at 2:38 PM | marketbeat.com

Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda

April 29 at 2:24 PM | nypost.com

Is Merck & Co., Inc. (MRK) the Worst-Performing Blue Chip Stock So Far in 2025?

April 29 at 1:09 PM | msn.com

Merck to build $1B Delaware plant to ensure domestic supply of Keytruda

April 29 at 8:08 AM | msn.com

California State Teachers Retirement System Sells 59,042 Shares of Merck & Co., Inc. (NYSE:MRK)

April 29 at 7:59 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Northern Trust Corp

April 29 at 7:52 AM | marketbeat.com

The Manufacturers Life Insurance Company Sells 73,853 Shares of Merck & Co., Inc. (NYSE:MRK)

April 29 at 7:49 AM | marketbeat.com

Beacon Pointe Advisors LLC Has $23.47 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

April 29 at 7:20 AM | marketbeat.com

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware

April 29 at 7:04 AM | businesswire.com

Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports

April 29 at 6:01 AM | reuters.com

Merck will build a $1 billion plant to expand U.S. manufacturing as tariff threats loom

April 29 at 5:30 AM | wsj.com

Merck & Co., Inc. (NYSE:MRK) Receives Average Rating of "Moderate Buy" from Analysts

April 29 at 5:06 AM | marketbeat.com

Is Merck & Co., Inc. (MRK) the Most Profitable Blue Chip Stock to Buy Now?

April 28 at 9:38 AM | insidermonkey.com

2 Must-Own Dividends At Bargain Basement Prices

April 28 at 9:18 AM | seekingalpha.com

Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?

April 28 at 8:50 AM | zacks.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Public Employees Retirement Association of Colorado

April 28 at 7:22 AM | marketbeat.com

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

April 28 at 2:33 AM | wsj.com

Merck & Co., Inc. (MRK): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential

April 27 at 3:29 PM | insidermonkey.com

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

April 27 at 12:00 PM | businesswire.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Prosperity Consulting Group LLC

April 27 at 7:16 AM | marketbeat.com

6,119 Shares in Merck & Co., Inc. (NYSE:MRK) Acquired by Bolthouse Investments LLC

April 27 at 6:54 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
By Thomas Hughes | April 25, 2025
View If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
By Leo Miller | April 28, 2025
View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
By Chris Markoch | April 16, 2025
View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

BMY, JNJ, ABBV, and MRK Company Descriptions

AbbVie NYSE:ABBV

$195.14 +2.80 (+1.45%)

As of 02:44 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol-Myers Squibb NYSE:BMY

$49.39 +0.93 (+1.91%)

As of 02:44 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson NYSE:JNJ

$156.44 +1.09 (+0.70%)

As of 02:44 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$84.85 +1.66 (+1.99%)

As of 02:44 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time